A novel therapeutic vaccine targeting the soluble TNFα receptor II to limit the progression of cardiovascular disease: AtheroVax™

Iversen, P. L., Kipshidze, N., Kipshidze, N., Dangas, G., Ramacciotti, E., Kakabadze, Z., & Fareed, J. (2023). A novel therapeutic vaccine targeting the soluble TNFα receptor II to limit the progression of cardiovascular disease: AtheroVax™. Frontiers in Cardiovascular Medicine, 10. https://doi.org/10.3389/fcvm.2023.1206541
Authors:
Patrick L Iversen
Nicholas Kipshidze
Nodar Kipshidze
George Dangas
Eduardo Ramacciotti
Zurab Kakabadze
Jawed Fareed
Affiliated Authors:
Nodar Kipshidze
Columbia Affiliation:
Author Keywords:
tnfrii
atherosclerotic cardiovascular disease
peptide vaccine
soluble tnfrii
therapeutic vaccine
tumor necrosis factor alpha
elink
Publication Type:
Article
Unique ID:
10.3389/fcvm.2023.1206541
PMID:
37534280
DOI:
10.3389/fcvm.2023.1206541
Journal:
Frontiers in Cardiovascular Medicine
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: